Combination therapy of gemcitabine or oral S-1 with the anti-VEGF monoclonal antibody bevacizumab for pancreatic neuroendocrine carcinoma

Experimental and Therapeutic Medicine

Volumn 3, Issue 4, 2012, Pages 599-602

  Kasuya, Kazuhiko ^a   Nagakawa, Yuichi ^a   Suzuki, Minako ^a   Suzuki, Yoshiaki ^a   Kyo, Bunso ^a   Suzuki, Satoru ^a   Matsudo, Takaaki ^a   Itoi, Takao ^a   Tsuchida, Akihiko ^a   Aoki, Tatsuya ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Antibody; Gemcitabine; Neuroendocrine carcinoma; Pancreas; S 1; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER TRANSPLANTATION; CONTROLLED STUDY; DRUG EFFICACY; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PANCREAS NEUROENDOCRINE CARCINOMA; TREATMENT DURATION; TUMOR VOLUME;

EID: 84863047255     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.456     Document Type: Article

References (21)

1. Eriksson B and Oberg K: Neuroendocrine tumours of the pancreas. Br J Surg 87: 129-131, 2000.
2. Takahashi Y, Akishima-Fukasawa Y, Kobayashi N, et al: Prognostic value of tumor architecture, tumor-associated vascular characteristics, and expression of angiogenic molecules in pancreatic endocrine tumors. Clin Cancer Res 13: 187-196, 2007.
3. Miljković MD, Girotra M, Abraham RR and Erlich RB: Novel medical therapies of recurrent and metastatic gastroenteropancreatic neuroendocrine tumors. Dig Dis Sci 57: 9-18, 2011.
4. Jain RK, Duda DG, Clark JW and Loeffler JS: Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3: 24-40, 2006.
5. Kasuya K, Nagakawa Y, Suzuki M, Tanaka H, Ohta H, Itoi T and Tsuchida A: Anti-vascular endothelial growth factor antibody single therapy for pancreatic neuroendocrine carcinoma exhibits a marked tumor growth-inhibitory effect. Exp Ther Med 2: 1047-1052, 2011.
6. Grindey GB, Hertel LW and Plunkett W: Cytotoxicity and antitumor activity of 2',2'-difluorodeoxycytidine (gemcitabine). Cancer Invest 8: 313-318, 1990.
7. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7: 548-557, 1996.
8. Georgieva I, Koychev D, Wang Y, Holstein J, Hopfenmüller W, Zeitz M and Grabowski P: ZM447439, a novel promising aurora kinase inhibitor, provokes antiproliferative and proapoptotic effects alone and in combination with bio- and chemotherapeutic agents in gastroenteropancreatic neuroendocrine tumor cell lines. Neuroendocrinology 91: 121-130, 2010.
9. Shah DK, Veith J, Bernacki RJ and Balthasar JP: Evaluation of combined bevacizumab and intraperitoneal carboplatin or paclitaxel therapy in a mouse model of ovarian cancer. Cancer Chemother Pharmacol 68: 951-958, 2011.
10. Braakhuis BJ, Ruiz van Haperen VW, Boven E, Veerman G and Peters GJ: Schedule-dependent antitumor effect of gemcitabine in in vivo model system. Semin Oncol 4 (Suppl 11): 42-46, 1995.
11. Fukushima M, Satake H, Uchida J, et al: Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts. Int J Oncol 13: 693-698, 1998.
12. Nakahira S, Nakamori S, Tsujie M, et al: Pretreatment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effects in pancreatic cancer xenografts. Anticancer Res 28: 179-186, 2008.
13. Yao JC, Phan A, Hoff PM, et al: Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase ll study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. Clin Oncol 26: 1316-1323, 2008.
14. Pour PM and Kazakoff K: Stimulation of islet cell proliferation enhances pancreatic ductal carcinogenesis in the hamster model. Am J Pathol 149: 1017-1025, 1996.
15. Kindler HL, Niedzwiecki D, Hollis D, et al: Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28: 3617-3622, 2010.
16. Masellis AM, Sielaff TD and Bender GP: Successful treatment of metastatic pancreatic adenocarcinoma with combination chemotherapy regimens. Int J Clin Oncol 14: 478-481, 2009.
17. Nakai Y, Isayama H, Sasaki T, et al: Impact of S-1 on the survival of patients with advanced pancreatic cancer. Pancreas 39: 989-993, 2010.
18. Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Ohge H and Sueda T: Impact of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for adenocarcinoma of the body or tail of the pancreas. J Gastrointest Surg 13: 85-92, 2009.
19. Yamada Y, Yamaguchi T, Matsumoto H, et al: Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer. Invest New Drugs: Sept. 6, 2011 (E-pub ahead of print).
20. Oberg K, Akerström G, Rindi G and Jelic S; ESMO Guidelines Working Group: Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21 (Suppl 5): v223-v227, 2010.
21. Villaume K, Blanc M, Gouysse G, et al: VEGF secretion by neuroendocrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K/AKT/mTOR pathway. Neuroendocrinology 91: 268-278, 2010